Gain of a region on 7p22.3, containing MADILI, is the most frequent event in small-cell lung cancer cell lines

Small-cell lung cancer (SCLC) is a highly aggressive lung neoplasm, which accounts for 20% of yearly lung cancer cases. The lack of knowledge of the progenitor cell type for SCLC precludes the definition of a normal gene expression profile and has hampered the identification of gene expression changes, while the low resolution of conventional genomic screens such as comparative genomic hybridization (CGH) and loss of heterozygosity analysis limit our ability to fine-map genetic alterations. The recent advent of whole genome tiling path array CGH enables profiling of segmental DNA copy number gains and losses at a resolution 100 times that of conventional methods. Here we report the analysis of 14 SCLC cell lines and six matched normal B-lymphocyte lines. We detected 7p22.3 copy number gain in 13 of the 14 SCLC lines and 0 of the 6 matched normal lines. In 4 of the 14 cell lines, this gain is present as a 350 kbp gene specific copy number gain centered at MADILI (the human homologue of the yeast gene MADI). Fluorescence in situ hybridization validated the array CGH finding. Intriguingly, MADILI has been implicated to have tumor-suppressing functions. Our data suggest a more complex role for this gene, as MADILI is the most frequent copy number gain in SCLC cell lines.